Brief: Vanda Pharmaceuticals Announces EMA Positive Opinion For Orphan Drug Designation Of Imsidolimab For GPP
16/07/2026 23:22
BRIEF-Vanda Pharmaceuticals Announces EMA Positive Opinion For Orphan Drug Designation Of Imsidolimab For GPP July 16 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:
VANDA PHARMACEUTICALS - ANNOUNCES EMA POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION OF IMSIDOLIMAB FOR GPP
VANDA PHARMACEUTICALS - IMSIDOLIMAB BLA FOR GPP UNDER FDA REVIEW WITH TARGET ACTION DATE DECEMBER 12, 2026
Source text: ID:nPn859HCwa
Further company coverage: VNDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vanda Pharmaceuticals
See all newsUS STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons
US STOCKS ON THE MOVE-Walmart, Super Micro, FMC
US STOCKS ON THE MOVE-Nvidia, Penske Automotive, ManpowerGroup
US STOCKS ON THE MOVE-Barrick Mining, Venture Global, GE Vernova
Vanda Pharma shares slip as trial failure halts anxiety drug program